2017, Number 4
Rev Hematol Mex 2017; 18 (4)
Flores-Jiménez JA, Zambrano-Velarde MÁ, Vega-Cortés D, Tovar-Rojas KG, Gutiérrez-Aguirre CH, Gómez-Almaguer D
PDF size: 137.03 Kb.
ABSTRACTThe hematopoietic stem cell transplant has been done as a treatment for acute myeloid leukemia, in its different aspects and in patients with relapse or high risk. Molecular and cytogenetic tests have allowed us to make a correct evaluation and see which patient would benefit the most with the addition of a transplant as part of their therapeutic strategy. Individualizing the treatment for each patient according to their risk, age, clinical condition and the availability of a donor allows choosing the best induction therapy, consolidation and the addition or not of a transplant. In our environment, the incorporation of a transplant offers a combination of cytotoxicity and graft effect versus leukemia, which translates into a curative option for patients. Nowadays, the incorporation of the haploidentical transplant allows patients who do not have a compatible donor to be able to be rescued with favorable results. In the absence of novel, effective and accessible drugs to cure acute myeloid leukemia, transplantation has a preponderant role to give opportunity to patients who were destined to fail.